TABLE 2.
Parameters | Control | Lp‐10 | Lp‐20 | Lp‐40 | Lp‐60 | Lp‐80 | FA‐0.2 | FA‐0.5 | FA‐0.8 | FA‐1.1 | FA‐1.4 | FA‐1.7 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total motility (%) | 55.47±1.19de | 57.41±1.16d | 64.59±1.76bc | 68.45±1.69ab | 62.30±1.54c | 51.18±1.25f | 48.11±1.37g | 53.72±1.48ef | 58.24±1.56d | 64.07±1.89bc | 66.21±1.15b | 71.49±1.31a |
Progressive motility (%) | 25.31±1.84d | 25.74±1.52d | 31.26±1.38c | 36.43±1.75b | 30.14±1.96c | 19.02±1.47e | 15.69±1.20f | 22.10±1.33d | 26.77±1.09d | 30.07±1.50c | 33.84±1.16bc | 40.23±1.47a |
Control (C): Tris‐based extender without antioxidant; Lp‐10: Tris‐based extender + L‐proline (10 mM); Lp‐20: Tris‐based extender + L‐proline (20 mM); Lp‐40: Tris‐based extender + L‐proline (40 mM); Lp‐60: Tris‐based extender + L‐proline (60 mM); Lp‐80: Tris‐based extender + L‐proline (80 mM); FA‐0.2: Tris‐based extender + fulvic acid (0.2%); FA‐0.5: Tris‐based extender + fulvic acid (0.5%); FA‐0.8: Tris‐based extender + fulvic acid (0.8%); FA‐1.1: Tris‐based extender + fulvic acid (1.1%); FA‐1.4: Tris‐based extender + fulvic acid (1.4%); FA‐1.7: Tris‐based extender + fulvic acid (1.7%). Different superscripts within the same row demonstrate significant differences (p ≤ 0.05).